StockMarketWire.com - Pharmaceutical giants AstraZeneca and Daiichi Sankyo said their gastric cancer drug had been approved in the US.

The approval of enhertu by the Food and Drug Administration was based on positive results froma Destiny-Gastric01 phase-two trial conducted in Japan and South Korea.

Following US approval, AstraZeneca was due to pay $115 million to Daiichi Sankyo as part of a combined second-line and third-line milestone payment.





Story provided by StockMarketWire.com